tremelimumab,durvalumab,Sorafenib
AstraZeneca,Pfizer
['hcc', 'sorafenib']
#brunosangro presented long-term #os benefit of #stride in advanced #hcc. unprecedented one in four survival rate at 4 years #wcgic2023 
Associate Professor of Medical Oncology at HUNIMED, GI cancer specialist with research interest in #livercancer, #HCC, #biliarytractcancer, #cholangiocarcinoma